Neurological Disease

GPR17 agonist 2 (compound 10) is a human GPR17 agonist and selective P2Y receptor non-activator.GPR17 agonist 2 modulates intracellular cAMP levels through functional activation of its target receptor.GPR17 agonist 2 can be used for the research of multiple sclerosis, cerebral ischemia, traumatic brain injury, spinal cord injury.

SC13 is an orally active, selective Flap structure-specific endonuclease 1 (FEN1) inhibitor and mu opioid receptor (MOR) activator. SC13 impairs DNA damage repair and induces apoptosis in cancer cells. SC13 activates cGAS-STING signaling, increases chemokine secretion, and promotes CAR-T cell infiltration at solid tumour sites. SC13 can be used for the research of solid tumours and pain.

Axl/Mer/CSF1R-IN-2 (Comp 4) is a Axl, Mer and CSF1R inhibitor.

eNOS activator-1 is an orally active, blood-brain barrier permeable endothelial nitric oxide synthase (eNOS) activator. eNOS activator-1 upregulates eNOS mRNA expression, enhances endogenous NO biosynthesis, and activates the eNOS signaling pathway to maintain blood-brain barrier integrity. eNOS activator-1 upregulates the protein expression levels of PI3K, AKT, p-PI3K, and p-AKT. eNOS activator-1 reduces oxidative stress levels by decreasing lipid peroxidation and restoring antioxidant enzyme activities. eNOS activator-1 upregulates the expression of tight junction proteins ZO-1 and occludin, increases Cav-1 expression, and inhibits MMP-9-mediated blood-brain barrier disruption. eNOS activator-1 can be used in the research of ischemic stroke.

Proflavine sulfate is a multifunctional acridine compound. 3,6-Diaminoacridine sulfate is an acridine dye and also a DNA inserter. Proflavine sulfate is a potent broad-spectrum antibacterial agent, and its mechanism is to insert into bacterial DNA, interfering with replication and transcription, causing bacterial lysis. 3,6-Diaminoacridine sulfate is a K_ir3.2 potassium channel blocker and can be used to study the neurological phenotype of Down syndrome. 3,6-Diaminoacridine sulfate can penetrate the stratum corneum of the skin and accumulate in the cell nucleus and long-term exposure may induce skin cancer or other malignant tumors.

FUB 465 is an orally active inverse agonist at the constitutively active histamine H₃ receptor with a pK_i of 6.2 for H₃ receptor. FUB 465 can be used in the research of central nervous system diseases.

AChE/BChE-IN-28 (Compound 5q) is a BChE inhibitor with an IC₅₀ of 13.49 μM. AChE/BChE-IN-28 also exerts moderate inhibitory effect on AChE, with an IC₅₀ of 35.23 μM. AChE/BChE-IN-28 can be used in the research of Alzheimer's disease.

Dynorphin (2-17) (porcine) is a peptide derived from Prodynorphin, can improve somatic signs of Morphine-dependent withdrawal.

11β-HSD1-IN-11 (Compound c1a) is a competitive 11β-HSD1 inhibitor with IC₅₀s of 0.34 μM and 0.13 μM against rat and human 11β-HSD1, respectively.

mGlu4 receptor agonist 1 (compound 62) is a potent mGlu4 receptor positive allosteric modulator, with an EC₅₀ of 308 nM. mGlu4 receptor agonist 1 shows significant anxiolytic- and antipsychotic-like effect.

Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment.

Proterguride is a potent dopamine receptor agonist. Proterguride also shows antagonistic properties at the histamine H(1) receptor and alpha(1)-adrenoceptor and partially agonize serotonergic 5-HT2A/B receptor. Proterguride can be used for the research of neurological disease, such as Parkinson's disease .

Hexacosanoic acid (Standard) is the analytical standard of Hexacosanoic acid (HY-113301). This product is intended for research and analytical applications. Hexacosanoic acid is a very long-chain fatty acid. Abnormally elevated levels of Hexacosanoic acid are closely associated with various diseases, such as X-linked adrenoleukodystrophy, adrenomyeloneuropathy, atherosclerosis, and dementia.

Neuron-specific enolase, Human (EC 4.2.1.11), an enolase, is a biomarker in traumatic brain injury (TBI), stroke and anoxic encephalopathy after cardiac arrest and acute SCI as well.

Erucic acid-d₁₈-1 is the deuterium labeled Erucic acid (HY-N7109). Erucic acid, a monounsaturated fatty acid (MUFA), is isolated from the seed of Raphanus sativus L. Erucic acid can readily cross the blood-brain barrier (BBB), it has been reported to normalize the accumulation of very long-chain fatty acids in the brain. Erucic acid can improve cognitive impairment and be effective against dementia.

4-Hydroxypropranolol (hydrochloride) (Standard) is the analytical standard of 4-Hydroxypropranolol (hydrochloride). This product is intended for research and analytical applications. 4-Hydroxypropranolol hydrochlorid is an active metabolite of Propranolol. 4-Hydroxypropranolol hydrochlorid is of comparable potency to Propranolol. 4-Hydroxypropranolol hydrochlorid inhibits β1- and β2-adrenergic receptors with pA2 values of 8.24 and 8.26, respectively. 4-Hydroxypropranolol hydrochlorid has intrinsic sympathomimetic activity, membrane stabilizing activity and potent antioxidant properties.

SB-656104 is a potent antagonist of 5-HT₇ receptor, with the pK_i of 8.70, blocking 5-carboxamidotryptamine (5-CT) stimulated adenylyl cyclase activity.

BDS-I known as blood depressing substance, is a marine toxin which can be extracted from Anemonia sulcata. BDS-I is a specific inhibitor of Potassium Channel, targeting to Kv3.4. BDS-I inhibits Aβ1-42-induced enhancement of KV3.4 activity, caspase-3 activation, and abnormal nuclear morphology of NGF-differentiated PC-12 cells. BDS-I reverts the Aβ peptide-induced cell death.

PHD-1-IN-4 is a brain-penetrant PHD-1 inhibitor with an IC₅₀ of 0.074 μM.

Benzcyclane fumarate (Bencyclane fumarate; Benzcyclan fumarate) is a vasodilator with serotonin receptor antagonism. Benzcyclane fumarate exerts atypical serotonin antagonistic effects in rabbit superior mesenteric arteries. Benzcyclane fumarate relaxes high K⁺-induced contractions in rabbit basilar arteries and superior mesenteric arteries, and selectively inhibits sympathetic nerve stimulation-induced contractions in rabbit pulmonary arteries. Benzcyclane fumarate exerts non-competitive norepinephrine antagonistic effects in rabbit superior mesenteric arteries, and slightly reduces the maximum contractile response induced by histamine. Benzcyclane fumarate relaxes smooth muscles, induces transient hypotension, inhibits thrombosis, and accelerates blood fibrinolytic activity. Benzcyclane fumarate increases cerebral glucose content/uptake, enhances hypoxia tolerance in mice, and increases cerebral blood supply in dogs. Benzcyclane fumarate is applicable to studies related to cerebral vascular circulation.